Effects of laser on preventing decreased sensitivity in women with breast cancer during chemotherapy

Effects of laserpuncture in the prevention of altered tactile sensory perception in women with breast cancer during chemotherapy: randomized clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

REBEC

Registry ID

RBR-9wsg72

Enrollment

Unknown

Registered

2019-07-24

Start date

2018-07-05

Completion date

Unknown

Last updated

2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tactile Perception

Interventions

Experimental Group: 30 women with breast cancer will receive 12 concomitant sessions with 12 weeks of paclitaxel laser with 808nm of infrared laser at points IG4, ID3, C3, IG11, E36, BP9, VB34, F3 and

Radiation

E02.594.540

H02.004

Eligibility

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: Pathologic anatomic report of cancer; Beginning of treatment with antineoplastic chemotherapy containing taxanes, platines, vinca alkaloids and bortezomib alone or in combination; Absence of PSTA, identified by symptom reporting and stoichiometry test; Adults above 18 years.

Exclusion criteria

Exclusion criteria: Hoseniasis; Diabetes melittus; Cognitive deficits; Other neuropathies, including those caused by tumor infiltration; Absence of verbalization; Pregnant; Performance Status greater than or equal to 3; Acupuncture in the last 6 months for neuropathy; Alcoholism; Skin problems in the irradiated area; Presence of the tumor at the irradiation sites.

Design outcomes

Primary

Measure	Time frame
It is expected that the difference between the groups for tactile sensory perception is up to 30% by the stoichiometry and questionnaire of neuropathy induced by chemotherapy	—

Secondary

Measure	Time frame
Differences between groups for neuropathic pain are expected to be up to 5% for the neuropathic pain questionnaire Douleur neuropathique 4 questions;It is expected that the difference between the groups for anxiety is up to 60% for the Anxiety and Depression Scale (HADS);The difference between the groups for depression is expected to improve by up to 30% for the anxiety and depression questionnaire (Hospital Anxiety and Depression Scale - HADS);The difference between the groups for quality of life is expected to be up to 70% by the Functional Assessment of Cancer Therapy / Neurotoxicity (FACT / GOG-NTx)	—

Measure

Time frame

Differences between groups for neuropathic pain are expected to be up to 5% for the neuropathic pain questionnaire Douleur neuropathique 4 questions;It is expected that the difference between the groups for anxiety is up to 60% for the Anxiety and Depression Scale (HADS);The difference between the groups for depression is expected to improve by up to 30% for the anxiety and depression questionnaire (Hospital Anxiety and Depression Scale - HADS);The difference between the groups for quality of life is expected to be up to 70% by the Functional Assessment of Cancer Therapy / Neurotoxicity (FACT / GOG-NTx)

—

Countries

Brazil

Contacts

Public ContactAna;Tânia Lima Ramos Cardoso;Chianca

Hope Oncologia;Universidade Federal de Minas Gerais

enf.anacardoso@gmail.com;taniachianca@gmail.com+55(31)999131204;+55(31)3409-9829

Outcome results

None listed

Source: REBEC (via WHO ICTRP)